Pyruvate Dehydrogenase DeficiencySymptoms, Doctors, Treatments, Advances & More
Pyruvate Dehydrogenase Deficiency Overview
Learn About Pyruvate Dehydrogenase Deficiency
Pyruvate dehydrogenase deficiency is characterized by the buildup of a chemical called lactic acid in the body and a variety of neurological problems. Signs and symptoms of this condition usually first appear shortly after birth, and they can vary widely among affected individuals. The most common feature is a potentially life-threatening buildup of lactic acid (lactic acidosis), which can cause nausea, vomiting, severe breathing problems, and an abnormal heartbeat. People with pyruvate dehydrogenase deficiency usually have neurological problems as well. Most have delayed development of mental abilities and motor skills such as sitting and walking. Other neurological problems can include intellectual disability, seizures, weak muscle tone (hypotonia), poor coordination, and difficulty walking. Some affected individuals have abnormal brain structures, such as underdevelopment of the tissue connecting the left and right halves of the brain (corpus callosum), wasting away (atrophy) of the exterior part of the brain known as the cerebral cortex, or patches of damaged tissue (lesions) on some parts of the brain. Because of the severe health effects, many individuals with pyruvate dehydrogenase deficiency do not survive past childhood, although some may live into adolescence or adulthood.
The genes involved in pyruvate dehydrogenase deficiency each provide instructions for making a protein that is a component of a group of proteins called the pyruvate dehydrogenase complex. This complex plays an important role in the pathways that convert the energy from food into a form that cells can use. The pyruvate dehydrogenase complex converts a molecule called pyruvate, which is formed from the breakdown of carbohydrates, into another molecule called acetyl-CoA. This conversion is essential to begin the series of chemical reactions that produce energy for cells.
Pyruvate dehydrogenase deficiency is believed to be a rare condition; however, its prevalence is unknown.
Pyruvate dehydrogenase deficiency can have different inheritance patterns. When the condition is caused by mutations in the PDHA1 gene, it is inherited in an X-linked pattern. The PDHA1 gene is located on the X chromosome, which is one of the two sex chromosomes. In males, who have only one X chromosome, a mutation in the only copy of the gene in each cell is sufficient to cause the condition. A characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons.
Rosa Ferriero practices practicing medicine in Pozzuoli, Italy. Ms. Ferriero is rated as an Elite expert by MediFind in the treatment of Pyruvate Dehydrogenase Deficiency. She is also highly rated in 4 other conditions, according to our data. Her clinical expertise encompasses Pyruvate Decarboxylase Deficiency, Pyruvate Dehydrogenase Deficiency, Lactic Acidosis, and Maple Syrup Urine Disease.
Nicola Brunetti-Pierri is a Pediatrics specialist and a Medical Genetics provider practicing medicine in Houston, Texas. Dr. Brunetti-Pierri is rated as an Elite provider by MediFind in the treatment of Pyruvate Dehydrogenase Deficiency. He is also highly rated in 40 other conditions, according to our data. His clinical expertise encompasses Pyruvate Decarboxylase Deficiency, Crigler-Najjar Syndrome, Argininosuccinic Aciduria, and Rotor Syndrome.
Jirair Bedoyan is a Medical Genetics specialist and a Pediatrics provider practicing medicine in Pittsburgh, Pennsylvania. Dr. Bedoyan is rated as an Elite provider by MediFind in the treatment of Pyruvate Dehydrogenase Deficiency. He is also highly rated in 6 other conditions, according to our data. His clinical expertise encompasses Pyruvate Dehydrogenase Deficiency, Pyruvate Decarboxylase Deficiency, Dihydrolipoamide Dehydrogenase Deficiency, Urea Cycle Disorders (UCD), and Gastrostomy. Dr. Bedoyan is currently accepting new patients.
Summary: This is a phase II, multicenter, prospective, non-comparative clinical trial to assess the efficacy and safety of the treatment of pyruvate dehydrogenase deficiency (PDH) patients with glycerol phenylbutyrate (Ravicti®). The trial will be conducted with three visits: 3 day hospitalizations including clinical consultations and paramedical procedures at Month 0 (M0), Month 3 (M3), Month 6 (M6). Duri...
Summary: This is a medical research study to test a medication in patients with a disease called Pyruvate Dehydrogenase Complex (PDC) Deficiency. The medication is triheptanoin, which is currently FDA approved for the treatment of Long-Chain Fatty Acid Oxidation Disorders. Previous research suggests that triheptanoin may also be effective in the treatment PDC Deficiency. This study will investigate the saf...
Published Date: July 01, 2012
Published By: National Institutes of Health